Zoonotic Tuberculosis

Mycobacterium bovis and Other Pathogenic Mycobacteria

Charles O. Thoen, James H. Steele, John B. Kaneene, Charles O. Thoen, James H. Steele, John B. Kaneene

• Publisher: Wiley-Blackwell
• Year: 2014
• Print ISBN: 9781118474297
• eBook ISBN: 9781118474280
• Edition: 3
• Topic: Medicine
• Subtopic: Veterinary Medicine

Zoonotic Tuberculosis: Mycobacterium bovis and Other Pathogenic Mycobacteria, Third Edition is a comprehensive review of the state of the art in the control and elimination of infections caused by Mycobacterium tuberculosis complex in animals and humans. This update to the most complete and current reference available on Mycobacterium bovis includes new coverage of the latest molecular techniques; more information on human infection and One Health; updates to the information on the International Union Against Tuberculosis and Lung Disease (IUATLD), the World Health Organization (WHO), Pan American Health Organization (PAHO), and the United States Department of Agriculture's (USDA) National Tuberculosis Eradication Program; and coverage of additional Africancountries. The Third Edition upholds the book's reputation as a truly global resource on M. bovis.

Written by an international list of tuberculosis experts, chapters cover the status of tuberculosis in many regions throughout the world and deal with issues related to the detection, spread, and control of Mycobacterium bovis, as well as the economic impact of outbreaks. Zoonotic Tuberculosis: Mycobacterium bovis and Other Pathogenic Mycobacteria offers valuable information for public health officials, medical doctors, state and federal regulatory veterinarians, veterinary practitioners, and animal caretakers.

Chapter 1
Tuberculosis in animals and humans An introduction

Charles O. Thoen,¹ Philip A. LoBue,² and Donald A. Enarson ³

¹ Iowa State University, USA

² Centers for Disease Control and Prevention, USA

³ International Union Against Tuberculosis and Lung Disease, France

Tuberculosis is an important disease in animals and humans worldwide. It causes substantial morbidity, mortality, and economic loss. There is significant variation in terms of how different organisms of the M. tuberculosis complex affect specific animals, including humans. However, there are also important intersections between animals and humans with regard to TB. The best example is the occurrence of M. bovis disease in humans and domesticated and wild animals.

The tubercle bacillus infects an estimated 2 billion persons or approximately one third of the world's population, and it is estimated that 1.5 to 2 million people die from TB each year. Ninety-five percent of cases occur in people in developing countries. TB is one of the leading causes of infectious disease-related deaths worldwide [1]. The genus Mycobacterium includes several species that cause TB disease in humans and other animals. The Mycobacterium tuberculosis complex includes M. tuberculosis, M. cannettii, M. africanum, M. bovis, M. pinnipedii, M. mungi, M. caprae, and M. microti.

Significant progress has been made toward the elimination of TB caused by M. tuberculosis complex from humans in industrialized countries [2]. However, in many countries where TB programs have only recently been established, there has been only limited progress toward control of the disease. The development of drug-resistant (multidrug-resistant and extensively drug-resistant) strains has compromised the efficacy of TB treatment in humans and has markedly increased the cost associated with the use of multiple drug therapies [3]. Moreover, the susceptibility of human immunodeficiency virus (HIV)–infected individuals to M. tuberculosis complex is of major concern to public health officials in developing countries where the acquired immune-deficiency syndrome is rampant [4].

M. bovis accounts for only a small percentage of the reported cases of TB in humans; however, it is a pathogen of significant economic importance in wild and domestic animals around the globe, especially in countries where little information is available on the incidence of M. bovis infection in humans [5–7].

Tubercle bacilli were identified more than 130 years ago. However, a definitive understanding of the pathogenesis of the disease caused by the M. tuberculosis complex is deficient [8,9]. The tubercle bacillus enters the macrophage by binding to cell surface molecules of the phagocyte. Ingestion of the tubercle bacillus by phagocytes into the phagosome or intracytoplasmic vacuole protects the organism from the natural defenses in the serum. Following ingestion of the bacillus, lysosomes fuse with the phagosome to form phagolysosomes, and it is there that the phagocytes attempt to destroy the bacillus [10]. However, virulent bacilli have the ability to escape killing. Virulent mycobacteria survive inside a mononuclear phagocyte by inhibiting phagosome fusion with preformed lysosomes, thereby limiting acidification. It has been suggested that the pathogenicity of M. tuberculosis complex is a multifactorial phenomenon. However, in cases in which the host response is unable to destroy the bacillus due to conditions that compromise immune function, resulting in low CD4+ T-cell counts, such as immune suppression due to chemotherapy, stress, or HIV, reactivation may occur, resulting in the release of bacilli and transmission of infection.

The susceptibility of different host species varies for the M. tuberculosis complex, depending on the route of exposure, the dose of organisms, and the virulence of the strain [11]. Humans, nonhuman primates, and guinea pigs are very susceptible to M. tuberculosis. Cattle, rabbits, and cats are susceptible to M. bovis and are quite resistant to M. tuberculosis. Wild hoofed stock is generally susceptible to M. bovis, but few reports are available on the isolation of M. tuberculosis [12–14]. Swine and dogs are susceptible to both M. bovis and M. tuberculosis [15].

In humans, TB is a pulmonary and systemic disease caused by M. tuberculosis complex species, predominantly M. tuberculosis. TB infections occur when susceptible individuals inhale droplet nuclei containing tubercle bacilli and the droplet nuclei reach the alveoli of the lungs. The tubercle bacilli that reach the alveoli are ingested by alveolar macrophages and the majority of these bacilli are destroyed or inhibited. A small number multiply intracellularly and are released when the macrophages die. If alive, these bacilli may spread through the lymph or bloodstream to more distant tissues and organs, including areas in which TB disease is most likely to develop: the apices of the lungs, the kidneys, the brain, the bones, and through the lymphatic system to regional lymph nodes. This process of dissemination primes the immune system for systemic responses.

Because of the primed immune system, extracellular bacilli attract macrophages and other immunologically active cells. The immune response kills most of the bacilli, and the remaining bacilli are confined through the formation of granulomas. At this point, latent TB infection (LTBI) has been established, which may be detected using the Mantoux tuberculin skin test or interferon-gamma release assays. Within weeks after infection, the immune system is usually able to halt the multiplication of the tubercle bacilli, preventing further progression.

In some people, the tubercle bacilli overcome the defenses of the immune system and begin to multiply, resulting in the progression from LTBI to TB disease. This process may occur soon after or many years after infection. Unless treated, approximately 3%–5% of persons who have been infected with M. tuberculosis will develop TB disease in the first 2 years after infection, and another 2%–5% will develop disease at some time later in life. Thus, approximately 5%–10% of persons with normal immune systems who are infected with M. tuberculosis will develop TB disease at some point in their lives. Immunocompromised persons have a much higher risk of progression from infection to disease. For example, HIV-infected persons not receiving antiretroviral therapy have an 8% annual risk of progression [16].

TB continues to be an important disease both in humans and animals. It causes substantial morbidity, mortality, and economic loss worldwide. There is significant variation in terms of how different organisms of the M. tuberculosis complex affect specific animals, including humans. However, there are also important intersections between animals and humans with regard to TB. Perhaps the best example is the occurrence of M. bovis disease in humans and domesticated and wild animals.

M. bovis persists in humans, causing pulmonary and extrapulmonary disease. Unlike transmission of M. bovis from cattle to humans, the role of human-to-human airborne transmission in the spread of M. bovis has been somewhat controversial [17]; the predominant view has been that human-to-human transmission is a rare event and that it is only likely to occur in populations that are particularly susceptible to TB (e.g., HIV-infected persons). However, reports of clusters of cases with social and molecular epidemiologic links with patients with pulmonary M. bovis have suggested that human-to-human transmission does occur, even in nonimmunosuppressed persons [18].

Investigations are needed to elucidate the relative importance of M. bovis as regards TB incidence in humans, especially in developing countri...

Table of contents

• Cover
• Title page
• Copyright page
• Contributors
• Preface
• Chapter 1 : Tuberculosis in animals and humansAn introduction
• Chapter 2 : One Health approach for preventing and controlling tuberculosis in animals and humans
• Chapter 3 : Public health significance of zoonotic tuberculosis caused by the Mycobacterium tuberculosis complex
• Chapter 4 : Mycobacterium bovis infection in humans and animals with an emphasis on countries in Central and South America
• Chapter 5 : Pathogenesis of tuberculosis caused by Mycobacterium bovis
• Chapter 6 : Epidemiology of Mycobacterium bovis
• Chapter 7 : Molecular epidemiology of Mycobacterium bovis
• Chapter 8 : New and current approaches for isolation, identification, and genotyping of Mycobacterium bovis
• Chapter 9 : Tuberculosis in animals in South Africa
• Chapter 10 : Status and control of bovine tuberculosis in Ethiopia
• Chapter 11 : Distribution, public health significance, and control status of bovine tuberculosis caused by Mycobacterium bovis in Uganda
• Chapter 12 : Bovine tuberculosis
• Chapter 13 : Factors contributing to the transmission of bovine tuberculosis caused by Mycobacterium bovis and its control status in Sudan
• Chapter 14 : Overview of bovine tuberculosis in Ghana
• Chapter 15 : Status and control of tuberculosis in animals in Pakistan
• Chapter 16 : Zoonotic tuberculosis in humans, elephants, and other animals in Nepal
• Chapter 17 : Zoonotic tuberculosis in India
• Chapter 18 : An overview of Mycobacterium bovis infections in domestic and wild animals in Korea
• Chapter 19 : Mycobacterium bovis infection and control in China
• Chapter 20 : Zoonotic tuberculosis in Australia and New Zealand
• Chapter 21 : Bovine tuberculosis eradication in the United States
• Chapter 22 : The occurrence of M. bovis cases in U.S. cattle, 2001–2011
• Chapter 23 : The importance of M. bovis infection in cervids on the eradication of bovine tuberculosis in the United States
• Chapter 24 : Evaluation of antemortem diagnostic tests for detecting bovine tuberculosis infection in the United States
• Chapter 25 : Canada's bovine tuberculosis eradication program
• Chapter 26 : Bovine tuberculosis eradication program in Mexico
• Chapter 27 : Epidemiology of bovine tuberculosis in the Republic of Serbia with a brief overview of the current epidemiological situation in the region
• Chapter 28 : The impact of an integrated wildlife and bovine tuberculosis eradication program in Ireland
• Chapter 29 : Bovine tuberculosis eradication in France
• Chapter 30 : Animal tuberculosis in Spain
• Chapter 31 : Tuberculosis eradication in Italy
• Chapter 32 : Status of bovine tuberculosis control in countries of Central Europe and countries of the former Soviet Union
• Chapter 33 : Zoonotic tuberculosis in nonhuman primates
• Index
• End User License Agreement